BioNumerik is a leader in a powerful new area called “mechanism-based” drug discovery, which employs multi-disciplinary science, including chemistry, biology and quantum physics, integrated with high performance computational technologies, to identify, simulate and better understand the mechanisms by which drugs and their targets function. Our integrated approach aims to streamline drug development by selecting and optimizing promising drugs or compounds earlier in the discovery process, reducing the time and expense involved in laboratory testing. Our computational simulations attempt to approximate the way drugs function within the human body, giving an early assessment of the expected efficacy and safety of a new drug before time is spent in clinical or even preclinical trials.
Using our approach, we can design and develop compounds from a variety of starting points, including known drug classes, known or novel drug targets or genomic sequence data. Once we have identified the likely mechanisms of action of the target and characterized the properties of potential drug candidates, we use an iterative process of computer analysis and laboratory testing to select, study, and optimize the most promising candidates. We believe that this approach positions us to advance higher quality, lower risk candidates into clinical trials.
Mechanism-based drug discovery has been pioneered by Dr. Frederick Hausheer, our founder and an expert in pharmaceutical discovery, clinical oncology drug development, pharmacology and in the development and application of pharmaceutical discovery software and supercomputing applications. We believe our approach represents a novel method of drug discovery relative to drug screening, automated screening and combinatorial chemistry, and rational drug design.